Format

Send to

Choose Destination
Neoplasma. 2019 Mar 5;66(2):315-325. doi: 10.4149/neo_2018_180731N558. Epub 2018 Nov 23.

Ablative dose stereotactic body radiation therapy for oligometastatic disease: a prospective single institution study.

Author information

1
Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
2
Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
3
Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
4
Regional Center for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic.
5
Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic.
6
Radiation Oncology Department, Arthur James Cancer Center, The Ohio State University, Columbus, Ohio, United States.
7
Department of Nuclear Medicine and PET Center, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic.

Abstract

Localized, metastasis-directed stereotactic body radiation therapy (SBRT) of oligometastatic disease (OD) is currently rapidly evolving standard of care in many institutions. Further reports of outcomes are required to strengthen the level of evidence in the absence of comparative trials evaluating different practical procedures. The aim of this prospective single institutional study is to analyse, in unselected cohort of patients from real-world clinical practice, the long-term survival, tumor control outcomes and safety of SBRT in OD (radical ablative radiotherapy with biological equivalent dose BED10>100 Gy). In addition to standard toxicity and survival parameters, we report unique outcomes as FFWD - Freedom from widespread dissemination, FFNT - Freedom from the need of subsequent treatment and functional survival with Karnofsky performance status higher than 70%. A total of 110 patients were prospectively evaluated, 60% and 40% were treated for lung and liver oligometastatic disease, respectively. No grade 3 or 4 acute toxicities (CTCAE) were reported. With median follow up of 22.2 months and 2-year overall survival of 88.3%, four patients (6.1%) experienced local progression in the lung SBRT cohort. In the liver SBRT cohort, median follow up was 33 months, 2-year overall survival was 68.5% and 11 patients (25%) experienced local and 36 (81.8%) distal progression. Higher BED10 of 150-170 Gy compared to 100-150 Gy was an independent positive prognostic factor for local progression-free survival for all patients with hazard ratio 0.25. This confirms SBRT ablative radiobiology effects to be independent of OD primary histology and location. The best outcomes in terms of FFNT were observed in the multivariable analysis of patients with 1-2 lung OD compared to both the liver OD cohort and patients with more than 2 lung metastases. Better FFNT in the liver SBRT cohort was observed in patients with 1-2 liver metastases and in patients whose liver OD was irradiated by higher BED10. In conclusion, SBRT is a suitable option for patients who are not surgical candidates; with approximately 30% of patients not requiring subsequent treatment 2 years after SBRT. We believe that this treatment represents a safe and effective option for oligometastatic involvement in patients with various primary tumors.

PMID:
30509112
DOI:
10.4149/neo_2018_180731N558
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for AEPress, s r. o.
Loading ...
Support Center